Cargando…

The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer

The validated 17-gene Oncotype DX Genomic Prostate Score® (GPS™) assay risk-stratifies prostate-cancer patients with localized disease. The assay has primarily been utilized in lower risk patients deciding between active surveillance versus definitive therapy. In this retrospective cohort study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Helfand, Brian T., Paterakos, Michael, Wang, Chi-Hsiung, Talaty, Pooja, Abran, John, Bennett, John, Hall, David W., Lehman, Amy, Aboushwareb, Tamer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436076/
https://www.ncbi.nlm.nih.gov/pubmed/36048818
http://dx.doi.org/10.1371/journal.pone.0273782
_version_ 1784781279652216832
author Helfand, Brian T.
Paterakos, Michael
Wang, Chi-Hsiung
Talaty, Pooja
Abran, John
Bennett, John
Hall, David W.
Lehman, Amy
Aboushwareb, Tamer
author_facet Helfand, Brian T.
Paterakos, Michael
Wang, Chi-Hsiung
Talaty, Pooja
Abran, John
Bennett, John
Hall, David W.
Lehman, Amy
Aboushwareb, Tamer
author_sort Helfand, Brian T.
collection PubMed
description The validated 17-gene Oncotype DX Genomic Prostate Score® (GPS™) assay risk-stratifies prostate-cancer patients with localized disease. The assay has primarily been utilized in lower risk patients deciding between active surveillance versus definitive therapy. In this retrospective cohort study, we analyze the association of the GPS result with time to biochemical recurrence post-prostatectomy in patients with National Comprehensive Cancer Network® (NCCN) intermediate and higher risk prostate cancer. The 141 patients included in the study were from the NorthShore University HealthSystem diagnosed 2014–2019 with NCCN intermediate (n = 109) or higher risk (n = 32) prostate cancer, treated with radical prostatectomy 2015–2019. The association of GPS result with time to biochemical recurrence was evaluated using univariable and multivariable Cox proportional hazards models in 120 patients with unfavorable intermediate or higher risk. Median (interquartile range) follow-up time was 28 (20 to 38) months. The GPS result was significantly associated with time to biochemical recurrence as both a continuous and dichotomous variable in univariable (hazard ratio [HR] per 20 GPS units 2.36, 95% CI 1.45–3.80, p < 0.001; HR for GPS result 41–100 vs 0–40 3.28, 95% CI 1.61–7.19, p < 0.001) and in multivariable models accounting for NCCN risk group (HR per 20 GPS units 2.14, 95% CI 1.31–3.46, p = 0.003; HR for GPS result 41–100 vs 0–40 3.00, 95% CI 1.43–6.72, p = 0.003) or biopsy Gleason Score and diagnostic PSA or PSA density. These results indicate that the GPS assay was a strong predictor of biochemical recurrence after radical prostatectomy in this unfavorable intermediate and higher risk prostate cancer patient population.
format Online
Article
Text
id pubmed-9436076
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-94360762022-09-02 The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer Helfand, Brian T. Paterakos, Michael Wang, Chi-Hsiung Talaty, Pooja Abran, John Bennett, John Hall, David W. Lehman, Amy Aboushwareb, Tamer PLoS One Research Article The validated 17-gene Oncotype DX Genomic Prostate Score® (GPS™) assay risk-stratifies prostate-cancer patients with localized disease. The assay has primarily been utilized in lower risk patients deciding between active surveillance versus definitive therapy. In this retrospective cohort study, we analyze the association of the GPS result with time to biochemical recurrence post-prostatectomy in patients with National Comprehensive Cancer Network® (NCCN) intermediate and higher risk prostate cancer. The 141 patients included in the study were from the NorthShore University HealthSystem diagnosed 2014–2019 with NCCN intermediate (n = 109) or higher risk (n = 32) prostate cancer, treated with radical prostatectomy 2015–2019. The association of GPS result with time to biochemical recurrence was evaluated using univariable and multivariable Cox proportional hazards models in 120 patients with unfavorable intermediate or higher risk. Median (interquartile range) follow-up time was 28 (20 to 38) months. The GPS result was significantly associated with time to biochemical recurrence as both a continuous and dichotomous variable in univariable (hazard ratio [HR] per 20 GPS units 2.36, 95% CI 1.45–3.80, p < 0.001; HR for GPS result 41–100 vs 0–40 3.28, 95% CI 1.61–7.19, p < 0.001) and in multivariable models accounting for NCCN risk group (HR per 20 GPS units 2.14, 95% CI 1.31–3.46, p = 0.003; HR for GPS result 41–100 vs 0–40 3.00, 95% CI 1.43–6.72, p = 0.003) or biopsy Gleason Score and diagnostic PSA or PSA density. These results indicate that the GPS assay was a strong predictor of biochemical recurrence after radical prostatectomy in this unfavorable intermediate and higher risk prostate cancer patient population. Public Library of Science 2022-09-01 /pmc/articles/PMC9436076/ /pubmed/36048818 http://dx.doi.org/10.1371/journal.pone.0273782 Text en © 2022 Helfand et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Helfand, Brian T.
Paterakos, Michael
Wang, Chi-Hsiung
Talaty, Pooja
Abran, John
Bennett, John
Hall, David W.
Lehman, Amy
Aboushwareb, Tamer
The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer
title The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer
title_full The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer
title_fullStr The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer
title_full_unstemmed The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer
title_short The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer
title_sort 17-gene genomic prostate score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436076/
https://www.ncbi.nlm.nih.gov/pubmed/36048818
http://dx.doi.org/10.1371/journal.pone.0273782
work_keys_str_mv AT helfandbriant the17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer
AT paterakosmichael the17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer
AT wangchihsiung the17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer
AT talatypooja the17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer
AT abranjohn the17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer
AT bennettjohn the17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer
AT halldavidw the17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer
AT lehmanamy the17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer
AT aboushwarebtamer the17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer
AT helfandbriant 17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer
AT paterakosmichael 17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer
AT wangchihsiung 17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer
AT talatypooja 17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer
AT abranjohn 17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer
AT bennettjohn 17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer
AT halldavidw 17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer
AT lehmanamy 17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer
AT aboushwarebtamer 17genegenomicprostatescoreassayasapredictorofbiochemicalrecurrenceinmenwithintermediateandhighriskprostatecancer